Gilead Sciences Inc. (GILD)
Gilead Stock Surges on Strong Results in HIV Drug Study
Gilead Sciences (GILD) surged over 8% in intraday trading Thursday as the biotech firm announced a Phase 3 trial found its injectable lenacapavir was 100% effective in preventing HIV infection in women.
Gilead surges as HIV prevention therapy shows 100% efficacy in late-stage trial
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) shares added more than 8% after the pharmaceutical firm unveiled new data from a late-stage PURPOSE trial which showed its twice-yearly injectable HIV therapy lenacapavir is 100% effective in preventing HIV in women. Notably, lenacapavir was shown to be superior to once-daily oral Truvada, which is one of several medications currently used to treat HIV and to prevent HIV infection, known as pre-exposure prophylaxis (PrEP).
2 Pharma Stocks Moving in Different Directions Today
Stocks are all over the place today, with the Dow confidently higher, the Nasdaq choppy, and the S&P 500 contending with a psychologically-significant level.
Gilead Flashes A Bullish Sign After HIV Drug Proves 100% Effective
Gilead stock surged Thursday after its twice-annual shot proved 100% effective in preventing HIV infections in cisgender women.
Gilead's twice-yearly shot to prevent HIV succeeds in late-stage trial
Gilead's twice-yearly medicine to prevent HIV succeeded in a Phase 3 trial. None of the roughly 2,000 women in the trial who received the shot, lenacapavir, contracted HIV.
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Gilead's HIV prevention treatment found 100% effective in late-stage trial
Gilead Sciences Inc.'s stock GILD jumped 4.5% early Thursday after the company said its experimental twice-yearly injection for HIV prevention was found 100% effective in a late-stage trial.
Gilead's long-acting HIV drug superior to daily pill Truvada in study
Gilead Sciences said on Thursday a late-stage study showed its injectable drug, lenacapavir, was more effective in preventing HIV infection in women compared to the company's existing daily pill Truvada.
Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar
Gilead stock jumped Friday after surprising Wall Street with preclinical test results for an under-the-radar weight-loss drug.
Gilead Stock Gains. It's Trying to Get Into the Obesity Drug Game.
A success would be a gamechanger for the biotech company known for its HIV treatments.
Gilead Sciences (GILD) Stock Dips While Market Gains: Key Facts
The latest trading day saw Gilead Sciences (GILD) settling at $63.56, representing a -1.21% change from its previous close.
Gilead Sciences, Inc. (GILD) Goldman Sachs 45th Annual Global Healthcare Conference (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) Goldman Sachs 45th Annual Global Healthcare Conference June 12, 2024 1:20 PM ET Company Participants Daniel O'Day - Chairman and Chief Executive Officer Conference Call Participants Salveen Richter - Goldman Sachs Salveen Richter Good afternoon, everyone. Thank you so much for joining.
